TORONTO, ON / ACCESSWIRE / November 19, 2020 / Anaconda Mining Inc. ("Anaconda" or the "Company") (TSX:ANX)(OTCQX:ANXGF) is pleased to announce drill results from an ongoing 15,000-metre infill drill program ("Drill Program") at its 100%-owned Goldboro Gold Project ("Goldboro" or the "Project") in Nova Scotia, Canada. The Drill Program is designed to convert priority Inferred Mineral Resources into Measured and Indicated Mineral Resources of the Goldboro Deposit as part of the ongoing feasibility study.

The current drill results are all from shallow drilling (<175 vertical metres) at the West Goldbrook Gold System ("WG Gold System") at the western end of the Goldboro deposit and demonstrate numerous mineralized intersections consistent with the current resource model (Exhibit A). These results demonstrate that at shallow levels of the WG Gold System there are numerous mineralized zones that confirm the geometry and location of the modelled mineral resource. A total of eleven (11) visible gold occurrences were also observed in these drill holes.

Selected composited highlights from the Drill Program include:

28.52 grams per tonne ("g/t") gold over 2.0 metres (125.6 to 127.6 metres) including 112.87 g/t gold over 0.5 metres in hole BR-20-146;
1.85 g/t gold over 15.0 metres (184.0 to 199.0 metres) including 29.13 g/t gold over 0.5 metres and 9.12 g/t gold over 0.5 metres in hole BR-20-147;
3.99 g/t gold over 4.5 metres (186.0 to 190.5 metres) including 26.80 g/t gold over 0.5 metres in hole BR-20-177;
8.68 gold over 1.9 metres (127.6 to 129.5 metres) including 17.60 g/t gold over 0.9 metres in hole BR-20-160;
4.29 g/t gold over 3.6 metres (27.0 to 30.6 metres) including 26.70 g/t gold over 0.5 metres in hole BR-20-158;
6.65 g/t gold over 2.0 metres (23.0 to 25.0 metres) including 17.40 g/t gold over 0.5 metres in hole BR-20-176; and
3.72 g/t gold over 3.5 metres (76.0 to 79.5 metres) including 12.70 g/t gold over 0.5 metres in hole BR-20-182.

A table of selected composite intersections from the Drill Program are shown in Table 1 below.

"As the current drill program progresses, we continue to increase our understanding of the Goldboro mineral resource and importantly its scale in areas of conceptual open pit resources. The shallow infill drilling in the western end of the Goldboro deposit is important as it confirms the geometry and location of the mineral resource and provides further insight into the extent to which we may be able to profitably mine within an open pit at Goldboro. The drill results from this program will allow us to refine the mineral resource model and upgrade resources to the Measured and Indicated categories at West Goldbrook and other areas of the deposit, which will be incorporated into the ongoing definitive feasibility study."

~ Kevin Bullock, President and CEO, Anaconda Mining Inc.

To date, a total of 12,780.5. metres in 79 drill holes (BR-20-105 to BR-20-183) have been completed under the Drill Program, with assays from drill holes BR-20-105 to BR-20-142 previously reported in news releases dated September 3, 2020; October 5, 2020; and November 11, 2020. Current results for 5,075.0 metres in thirty-six (36) diamond drill holes (BR-20-143 to BR-20-183, excluding BR-20-157, -163, -167, -169 and -171 which were taken for comminution analysis) include intersections of mineralized zones primarily within the WG Gold System. Diamond drill hole BR-20-133 was sampled out of sequence and will be reported in a later communication once assays have been received and evaluated.

The Drill Program is funded using existing flow through funds but has also benefited from a grant received from the Government of Nova Scotia through a Mineral Resources Development Fund, shared funding exploration grant MRDF-2020-SF-035.

The Company has critically considered logistical matters given the ongoing COVID-19 pandemic, to ensure that this Drill Program and any other programs are executed in a way that ensures the absolute health and safety of our personnel, contractors, and the communities where we operate.

Table 1. Selected Composite Highlights Within This News Release From The Drill Program.

Hole ID

From (m)

To (m)

Interval (m)

Gold (g/t)

Visible Gold (VG)

BR-20-143

128.1

128.9

0.8

6.85

and

164.7

165.7

1.0

1.04

BR-20-144

98.7

99.2

0.5

4.47

and

106.9

107.6

0.7

7.22

and

119.5

120.1

0.6

4.70

BR-20-145

79.0

79.5

0.5

11.19

BR-20-146

21.0

22.0

1.0

16.28

VG

and

115.2

118.5

3.3

0.92

and

125.6

127.6

2.0

28.52

VG

including

126.1

126.6

0.5

112.87

BR-20-147

106.5

108.0

1.5

1.42

VG

and

184.0

199.0

15.0

1.85

including

184.0

185.5

0.5

29.13

including

189.5

190.0

0.5

9.12

BR-20-148

156.5

161.5

4.5

0.63

and

172.3

174.3

2.0

2.02

BR-20-149

31.0

33.0

2.0

5.92

including

31.0

32.0

1.0

10.61

and

53.0

56.0

3.0

1.58

BR-20-150

18.5

19.0

0.5

2.78

and

31.5

33.5

2.0

0.59

BR-20-151*

113.0

117.9

4.9

0.92

and

126.3

126.9

0.6

12.40

VG

and

148.0

149.0

1.0

2.41

and

160.2

161.7

1.5

0.70

BR-20-152*

53.5

54.0

0.5

2.63

BR-20-154*

130.0

131.5

1.5

1.18

and

144.5

145.0

0.5

3.52

BR-20-155*

29.5

30.5

1.0

2.04

BR-20-156*

42.0

42.5

0.5

4.17

and

65.0

65.5

0.5

2.30

BR-20-158*

27.0

30.6

3.6

4.29

including

28.0

28.5

0.5

26.70

and

60.0

61.0

1.0

1.94

and

88.9

96.5

7.6

0.94

including

90.4

90.9

0.5

3.82

and

103.1

105.1

2.0

6.15

including

104.1

105.1

1.0

11.45

BR-20-159*

103.5

104.5

1.0

5.31

and

153.4

153.9

0.5

8.28

and

201.2

202.7

1.5

7.41

BR-20-160*

22.6

23.3

0.7

1.94

and

86.3

87.7

1.4

2.11

and

115.7

117.2

1.5

0.72

and

127.6

129.5

1.9

8.68

including

127.6

128.5

0.9

17.60

BR-20-161*

133.5

134.5

1.0

1.61

BR-20-164*

114.0

115.0

1.0

1.06

BR-20-168*

27.5

29.0

1.5

1.10

and

66.6

67.8

1.2

1.14

BR-20-172*

17.5

18.0

0.5

2.47

BR-20-173*

128.0

130.6

2.6

1.51

VG

and

158.4

159.0

0.6

3.53

and

165.7

166.5

0.8

1.32

BR-20-174*

44.0

46.6

2.6

1.28

including

45.6

46.6

1.0

2.61

and

97.2

99.5

2.3

1.30

VG

and

111.3

112.3

1.0

1.51

BR-20-175*

17.0

18.0

1.0

2.41

and

30.8

32.3

1.5

0.67

VG

and

35.8

36.8

1.0

1.16

and

61.8

63.8

2.0

1.56

and

72.9

73.4

0.5

2.22

and

138.6

139.6

1.0

1.42

and

162.5

164.5

2.0

1.27

including

164.0

164.5

0.5

3.53

BR-20-176*

23.0

25.0

2.0

6.65

including

24.0

24.5

0.5

17.40

and

33.5

34.0

0.5

4.02

and

38.0

39.0

1.0

1.44

and

45.2

46.0

0.8

2.24

BR-20-177*

24.8

25.4

0.6

2.59

and

63.5

66.2

2.7

1.12

VG

including

63.5

64.0

0.5

3.35

VG

and

118.8

121.5

2.7

0.58

and

159.5

161.5

2.0

1.65

and

186.0

190.5

4.5

3.99

VG

including

188.5

189.0

0.5

26.80

VG

BR-20-178*

34.0

35.0

1.0

8.61

and

60.7

66.2

5.5

0.76

including

64.2

64.7

0.5

3.47

and

81.2

83.7

2.5

1.28

BR-20-179*

7.0

9.0

2.0

3.38

including

8.0

8.5

0.5

10.10

and

23.8

26.8

3.0

0.82

and

29.5

31.5

2.0

3.13

VG

including

30.5

31.0

0.5

8.21

BR-20-180*

18.0

19.5

1.5

0.90

BR-20-181*

129.0

131.9

2.9

0.99

BR-20-182*

33.5

34.0

0.5

2.95

and

69.6

71.1

1.5

1.91

and

76.0

79.5

3.5

3.72

VG

including

76.5

77.0

0.5

12.70

and

77.0

77.5

0.5

8.13

VG

and

91.5

92.0

0.5

3.90

BR-20-183*

13.0

14.0

1.0

3.50

BR-20-143*

128.1

128.9

0.8

1.32

*Fire Assay Only

This news release has been reviewed and approved by Paul McNeill, P. Geo., VP Exploration with Anaconda Mining Inc., a "Qualified Person", under National Instrument 43-101 Standard for Disclosure for Mineral Projects.

All samples and the resultant composites referred to in this release are collected using QA/QC protocols including the regular insertion of standards and blanks within the sample batch for analysis and check assays of select samples. All samples quoted in this release were analyzed at Eastern Analytical Ltd. in Springdale, NL, for Au by fire assay (30 g) with an AA finish.

For drill holes BR-20-143 to BR-20-150, samples analyzing greater than 0.5 g/t Au via 30 g fire assay were re-analyzed at Eastern Analytical Ltd. via total pulp metallics. For the total pulp metallics analysis, the entire sample is crushed to -10mesh and pulverized to 95% -150 – mesh. The total sample is then weighed and screened to 150mesh. The +150 – mesh fraction is fire assayed for Au, and a 30 g subsample of the -150 – mesh fraction analyzed via fire assay. A weighted average gold grade is calculated for the final reportable gold grade. Drill holes BR-20-151 to BR-20-183 reported as fire assay only. Total pulp metallics assays for these drillholes will be updated in a future news release.

Reported mineralized intervals are measured from core lengths. Intervals are estimated to be approximately 70-100% of true widths.

A version of this press release will be available in French on Anaconda's website (www.anacondamining.com) in two to three business days.

ABOUT ANACONDA

Anaconda is a TSX and OTCQX-listed gold mining, development, and exploration company, focused in Atlantic Canada. The company operates mining and milling operations in the prolific Baie Verte Mining District of Newfoundland which includes the fully-permitted Pine Cove Mill, tailings facility and deep-water port, as well as ~11,000 hectares of highly prospective mineral lands including those adjacent to the past producing, high-grade Nugget Pond Mine at its Tilt Cove Gold Project. Anaconda is also developing the Goldboro Gold Project in Nova Scotia, a high-grade resource and the subject of an on-going feasibility study.

FORWARD-LOOKING STATEMENTS

This news release contains "forward-looking information" within the meaning of applicable Canadian and United States securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Anaconda to be materially different from those expressed or implied by such forward-looking information, including risks associated with the exploration, development and mining such as economic factors as they effect exploration, future commodity prices, changes in foreign exchange and interest rates, actual results of current production, development and exploration activities, government regulation, political or economic developments, environmental risks, permitting timelines, capital expenditures, operating or technical difficulties in connection with development activities, employee relations, the speculative nature of gold exploration and development, including the risks of diminishing quantities of grades of resources, contests over title to properties, and changes in project parameters as plans continue to be refined as well as those risk factors discussed in Anaconda's annual information form for the year ended December 31, 2019, available on www.sedar.com. Although Anaconda has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Anaconda does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

FOR ADDITIONAL INFORMATION CONTACT:

Anaconda Mining Inc.
Kevin Bullock
President and CEO
(647) 388-1842
kbullock@anacondamining.com

Reseau ProMarket Inc.
Dany Cenac Robert
Investor Relations
(514) 722-2276 x456
Dany.Cenac-Robert@ReseauProMarket.com

Anaconda Mining Inc.
Lynn Hammond
VP, Corporate Affairs
(709) 330-1260
lhammond@anacondamining.com

Exhibit A: A map showing the location of drill holes and selected composited highlights referred to in this news release.

SOURCE: Anaconda Mining Inc.

ReleaseID: 617486

Market players are focusing on extending their market worldwide together with bringing an expanded product portfolio to attain an edge over the competitors.

DUBAI, UAE / ACCESSWIRE / November 19, 2020 / Future Market Insights: The tape dispenser market will grow at a CAGR of 3.8% over the forecast period, 2020-2030. The market growth can be primarily attributed to logistics and e-commerce industries. Growing online sales volumes of non-essential and essential products has amplified the requirement for effective packaging solutions, producing prospects for tap dispenser manufacturers.

"Escalated requirement for precision-based packaging solutions is boosting vendors to integrate technological developments such as AI to provide quality solutions to key end-users." concludes the FMI analyst.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-2822

Tape Dispenser Market – Key Highlights

North America to remain the leading region poised to record a CAGR of 4% by 2030 end.
Table top dispensers is estimated to generate maximum revenue share by the end of 2030.
Automatic Tape Dispensers will record a CAGR of 4.3% during the forecast period.
Commercial & office usage to gain traction among other end use segments by 2030 end.

Tape Dispenser Market – Drivers

Escalating online food delivery market are catalyzing the need for advanced packaging solutions, thereby boosting the demand for tape dispensers.
Growing sales through e-commerce platforms support demand for advanced packaging solutions, ultimately offering prospects to tape dispenser manufacturers.
Technological innovations such as automated tape dispensers are estimated to offer new prospects to the tape dispenser market players

Tape Dispenser Market – Restraints

Several structural issues such as invisible starting point of the tape, proves to be a limitation to future growth.
Emitting undesired noises upon usage and not being sound-friendly restraints their application.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-2822

COVID-19 Impact on the Market

The tape dispenser market have been adversely impacted by the COVID-19 outbreak. The market is poised to record a downturn of -0.2% in 2020. However as per FMI's recent report, the market is anticipated to regain pace once the restriction imposed by the lockdowns are lifted. Need for e-commerce and logistics rest highly on constant supplies of essential products. Therefore, the requirement for remarkable packaging solutions increased demand for tape dispensers, and will keep it afloat.

Competitive Landscape

Key companies players identified in the tape dispenser market are Tesa SE, 3M Company, Fellow Brands, Intertape Polymer Group Inc., Koziol USA, Shurtape Technologies LLC, Prisma Pressure Sensitive Products Ltd., START International, Aroindia Electromech Pvt. Ltd. and Spec-Tech (Xiamen) Co. Ltd. Companies are engaged in expanding their outreach in the back of acquisitions, collaborations and product launches.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/2822

About the Study

The study offers readers a comprehensive assessment of the tape dispenser market. Global, regional and national-level analysis of the latest trends influencing the market is covered in this FMI report. The study provides insights according to product type (hand held, table top, definite length dispensers and stretchable tape dispensers), by technology (automatic and manual), by end use (office & commercial and industrial) across key regions (North America, Latin America, Europe, China, Asia Pacific, Middle East & Africa).

Table Of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Market Analysis

1.3. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage

2.2. Market Definition

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation Trends

4. Key Success Factors

4.1. Product Adoption Analysis

4.2. Product USPs / Features

5. Global Tape Dispenser Market Demand Analysis 2015-2019 and Forecast, 2020-2030

5.1. Historical Market Volume (‘000 Units) Analysis, 2015-2019

5.2. Current and Future Market Volume (‘000 Units) Projections, 2020-2030

5.3. Y-o-Y Growth Trend Analysis

6. Global Tape Dispenser Market – Pricing Analysis

6.1. Regional Pricing Analysis

6.2. Pricing Break-up

6.3. Global Average Pricing Analysis Benchmark

Download Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-2822

Explore FMI's Coverage of the Packaging Industry

Water Activated Tape Dispensers Market: Get insights on the water activated tape dispensers market through FMI's report covering detailed quantitative and qualitative analysis for projection period 2017 – 2027.

Tear Tape Dispenser Market: FMI's exhaustive study on the global tear tape dispenser market covers the latest trends, innovations, key players, and popular strategies for the period 2020 – 2030.

Holographic Tear Tape Market: Obtain detailed analysis on the holographic tear tape market through FMI's report covering competitive analysis, key regions, and segmental analysis for 2019 – 2029.

About Future Market Insights

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: sales@futuremarketinsights.com

For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/tape-dispenser-market

Press Release Source: https://www.futuremarketinsights.com/press-release/tape-dispenser-market

SOURCE: Future Market Insights

ReleaseID: 617557

VANCOUVER, BC / ACCESSWIRE / November 19, 2020 / Sativa Wellness Group Inc. (CSE:SWEL) ("Sativa Wellness" or the "Company") is pleased to announce that as part of Sativa Wellness' commitment to safety and wellness in our communities, we are launching a private COVID-19 testing clinic inside our Goodbody Wellness store in Bath on 19th November.

The clinic will be providing PCR testing for travel and work, antigen testing (results in 15 minutes) as well as antibody testing for those who want to find out if they have had COVID 19 and to see if they have developed antibodies.

Customers book an appointment online, and will attend in-store to self-administer the test guided by a trained medical professional. The Company is already seeing strong demand in pre-bookings for this service.

Sativa Wellness provides numerous products to help customers during these challenging times, including our popular Goodbody Wellness CBD with vitamin D, and a complete range of hand sanitiser products designed for use in restaurants, businesses and for personal use, available in-store or online at "https://www.goodbodystore.com".

The UK Government is evaluating a ‘Test to Release' scheme which is expected to reduce the quarantine period after travelling abroad, by taking a test five or seven days after returning to the UK. However, negative tests are already a requirement when travelling to a number of countries from the UK. Appointments should be made in line with the Government guidelines on when your test is required for travel.

The private clinic is designed for people who aren't presenting symptoms but who need a negative test for travel, work or peace of mind when visiting vulnerable relatives. Anyone with symptoms should instead book an NHS test and follow the Government isolation procedures.

The PCR lab test is a swab sent for analysis at an accredited laboratory to test for the presence of COVID-19. A certificate delivered direct via email and SMS is provided to permit travelling and pass immigration. The test is 98% sensitive if the virus is found on the swab and has a 48-72-hour turnaround. The test cost £155.

A rapid antigen test is also available, which checks whether you are carrying the COVID-19 virus and could be infectious to others. Sensitivity is 92.5% and Specificity is 99.8%. Results are available in 15 minutes and the test costs £75.

Finally, an IgG and IgM rapid antibody test costing £55 is available which tests to see if you have already had COVID-19 and have developed antibodies. The test has an accuracy of 98.3% and results are available in just 15 minutes.

According to George Thomas, Managing Director of Goodbody Botanicals, "Our expertise in good health and wellbeing made it an obvious transition to be able to offer COVID testing in our store. The same attention to detail and care has been taken to ensure we can offer the best testing in a safe, calm environment. We hope this service will give people the peace of mind, and proof, required to return to travel, work and visiting friends and family when this is possible".

For more information or to book an appointment visit https://www.goodbodyclinic.com

The Directors of the Company accept responsibility for the contents of this announcement.

Further information regarding the Company can be found at www.sedar.com.

On behalf of the Board of Directors,

Henry Lees-Buckley
Chief Executive Officer
Sativa Wellness Group Inc.
+44 (0) 20 7971 1255
enquiries@sativawellnessgroup.com
www.sativawellnessgroup.com

Joseph Colliver
Chief Financial Officer
Sativa Wellness Group Inc.
+44 (0) 20 7971 1255
enquiries@sativawellnessgroup.com
www.sativawellnessgroup.com

Jason Dussault
Investor Relations and Communications
Sativa Wellness Group Inc.
jason@sativawellnessgroup.com
www.sativawellnessgroup.com

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Stillcanna's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" "plan is" or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur", "will be achieved" or "shortly". The forward-looking information and forward-looking statements contained herein include, but are not limited to information concerning the COVID-19 testing clinic, the accuracy of the results of the COVID-19 tests, and the availability of COVID-19 tests.

Although Sativa Wellness believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that any sales, profits or revenues will be derived from the agreement with the Health Store. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and Sativa does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

SOURCE: Sativa Wellness Group Inc.

ReleaseID: 617447

COLLEGE STATION, TX / ACCESSWIRE / November 19, 2020 / Strategic Vaccines, LLC today announced that Lockheed Martin will conduct a computational study of the Strategic Vaccines' proprietary manufacturing systems designed to address emerging viral threats, beginning with COVID-19.

These proprietary Test and Go Rapid Deployment (TANGO-RDP) manufacturing systems will be housed at the Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) at College Station.

"Strategic Vaccines is manufacturing FLOVID-20, an inhaled treatment for COVID-19 designed to keep patients out of the hospital," said Reid Rubsamen, M.D., CEO, Strategic Vaccines, LLC. "The TANGO-RDP manufacturing systems we'll establish at the Texas A&M CIADM site will enable us to quickly address emerging viral threats. Lockheed Martin has a unique skill set matching our requirements and is helping us with that process."

The FLOVID-20 therapeutic is stable at room temperature and designed for delivery by inhalation to patients with a positive COVID-19 test. Strategic Vaccines, LLC is manufacturing FLOVID-20 at it's partner company Oakwood Laboratories in Solon, Ohio, and expects to begin clinical trials next year.

"Lockheed Martin's work with Strategic Vaccines at Texas A&M is a great opportunity to apply our technical resources and experience to help defeat the COVID-19 threat," said Michele Evans, Executive Vice President of Lockheed Martin Aeronautics. "This exemplifies one of our core values – ‘Do What's Right' – by using our unique aerospace expertise to serve a global need."

"The Texas A&M System is tirelessly working to respond to this deadly pandemic," said John Sharp,Chancellor of The Texas A&M University System. "We welcome Strategic Vaccines new teammate Lockheed Martin into our Texas A&M CIADM ecosystem."

About Strategic Vaccines

Strategic Vaccines, LLC is a Public Private Partnership ("PPP") including San Francisco Bay Area Biotech Flow Pharma, Inc. defense contractor M7TecGroup, Texas A&M University and Solon, Ohio based Oakwood Laboratories, LLC.

About Lockheed Martin

Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 110,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

About the Texas A&M Center for Innovation in Advanced Development and Manufacturing

The Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) is founded on an initial $285.6 million public-private partnership with the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA). The public/private partnership includes an initial investment of $176.6 million from the U.S. government with the remainder cost-shared by commercial and academic partners as well as the State of Texas Emerging Technology Fund. The Center for Innovation was awarded to the Texas A&M University System in June 2012 and is part of a national strategy recommended in the August 2010 Public Health Emergency Medical Countermeasures Enterprise Review.

As one of three centers established as public-private partnerships with the U.S. Department of Health and Human Services to develop and manufacture countermeasures, the Texas A&M Center for Innovation will respond to the need for rapid and flexible manufacturing to bolster the nation's ability to respond to any attack or threat, including novel, previously unrecognized, naturally occurring emerging infectious diseases, as well as various chemical, biological, radiological and nuclear threats.

It is designed to facilitate rapid research and development (R&D), promote novel product development through both public and private partnerships, ensure domestic manufacturing surge capacity, assist in FDA approval of products, as well as mentor the next generation of public health professionals through workforce training and outreach. The center will not only enhance the nation's ability to produce life-saving countermeasures quickly and nimbly, it will also transition processes and technologies that will broadly impact both national and global public health.

The Center is part of the Public Health Preparedness and Response initiative that has been established at the Texas A&M Health Science Center (TAMHSC).

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. ("the Company"), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.

Media Contact:

ir@strategicvaccines.com

Strategic Vaccines, LLC
1041 Rellis Parkway, Suite 2312
College Station, Texas 77807

SOURCE: Strategic Vaccines, LLC

ReleaseID: 617505

DESTIN, FL / ACCESSWIRE / November 19, 2020 / Over 237,000 combat sports fans around the world downloaded the GoTV HD app after the official Xtreme Fighting Championships (OTC PINK:DKMR) channel was promoted on the XFC 43 broadcast on NBC Sports Network and FITE TV.

Launched earlier this month, the XFC's official home on GoTV HD is Channel 101. On the channel, MMA fans around the world have access to hundreds of hours of exclusive XFC content, including original content, behind-the-scenes footage, and all the best fights from the XFC vault.

XFC President Myron Molotky is pleased by the news, and says the dramatic uptick in downloads speaks to the reach and enthusiasm of XFC's global fan base.

"Mixed martial arts fans, especially fans of the XFC, are constantly craving to be closer to the action, and that's exactly where GoTV HD puts them. We're very excited to see so many combat sports fans get on board, because there's a whole world of XFC Hexagon action available, at your fingertips."

About XFC

Xtreme Fighting Championships, Inc. (formerly Duke Mountain Resources, Inc.) is the first publicly traded premier international mixed martial arts ("MMA") organization with offices throughout the United States and South America, trading under the ticker symbol DKMR. Xtreme Fighting Championships ("XFC") is now partnered with NBC Sports in the United States, and has previously been carried on some of the largest open television broadcasters in Latin America – Rede TV! as well as HBO, ESPN, Esportes Interativo, Terra TV (the largest internet portal in the world), and UOL – the largest internet portal in Latin America, and premium cable & satellite television network. The XFC has had over 185 exclusively signed fighters, representing over 35+ countries worldwide with even more growth expected. Boasting the signing of The Next Generation of Male & Female Superstars, the XFC is known for entertaining fans with the most action packed MMA events both on television and in stadium venues. The Next Generation of MMA.

About GoTV HD

GoTV HD is a new breed of OTT Live Broadcast Platform Entertainment fully controlled and owned by Global Oculus Media LLC. The OTT service is established to provide Live TV with rewind capabilities to US and worldwide markets accessible on web, mobile (iOS and Android) and Smart TV. This service caters to the underserved audiences and cord cutters with a freemium model for basic channels, subscription offers in skinny bundles, prepaid service that can be distributed in 11,000 brick-and-mortar locations. The network provides unparalleled speeds through its exclusive global telecom carriers with domestic and international network capabilities. The network has transport and PPV capabilities with unique positioning in the cable and OTT market distribution around the world. GO LIVE…GO STREAM…GO ANYWHERE.

Press Contact:

Jen Wenk, APR
jenwenkpr@gmail.com / 208.421.2919

CONTACT: Xtreme Fighting Championships, Inc.

ReleaseID: 617451

Industry Veterans Bring Deep Expertise and Experience to Tarus Board

NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, today announced the appointments of Mark Cohen as Chairman of the Board, and Robert Glassman, MD PhD, as a new Board Director (effective January 1, 2021).

Dr. Glassman has been a senior investment banker for 17 years, at Merrill Lynch for the majority of his career and as Vice Chairman at Credit Suisse since 2015. On transitioning from banking to OrbiMed Advisors, one of the world's largest dedicated healthcare investment firms, Dr. Glassman will be their only venture partner in public equity; he had been a private equity partner at OrbiMed 2009-2010. Earlier in his career, Dr. Glassman was with Merrill Lynch Global Private Equity where he oversaw a very successful healthcare portfolio and at McKinsey & Company for four years, where he consulted for a wide range of healthcare clients in the U.S. and Europe. Dr. Glassman is a board certified hematologist-oncologist who remains on the faculty as a Clinical Assistant Professor of Medicine at Weill Cornell. He has co-authored numerous articles in peer-reviewed journals and spoken widely in industry and academic forums on oncology clinical development, reimbursement, and data interpretation. Dr. Glassman has an AB from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Weill Cornell. He also spent several years as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received Howard Hughes Medical Institute and American Cancer Society awards.

Mr. Cohen is a founder of Pearl Cohen Zedek Latzer Baratz LLP, Senior Partner, Chair of the Life Sciences Practice Group, and a member of the firm's Executive Committee. Mark was a Board Director of Masthercell Global, Inc., a subsidiary of Orgenesis, Inc. (NASDAQ: ORGS), prior to its acquisition in February 2020 by Catalant, Inc. He was also Vice-Chairman of the Board and Chairman of Governance at Akari Therapeutics, Plc.

"I am excited to be joining the Board of Tarus as the company prepares to move from pre-clinical to clinical development, and honored to take on the role of Chairman," said Mr. Cohen. "I believe there is a significant opportunity for each of our programs in multiple cancer settings, as well as non-oncology indications. I look forward to working with the company to create value for patients and all stakeholders."

"Tarus is diligently advancing its oncology portfolio with the programs slated to enter clinic in early 2021. I look forward to supporting the team through this important inflection in the Company's development," added Dr. Glassman.

"We are delighted to welcome Mark and Robert to our Board of Directors at this exciting and significant phase for Tarus Therapeutics as we prepare to initiate multiple clinical studies," stated Dr. Sushant Kumar, Board Member and Chief Executive Officer of Tarus Therapeutics, Inc. "The addition of new directors complements our skills and experiences and we look forward to their guidance in bringing innovative and impactful immunotherapies to cancer patients."

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.

Contact:

Tarus Therapeutics, Inc.
Sushant Kumar, PhD
President & CEO
info@tarustx.com

SOURCE: Tarus Therapeutics, Inc. via EQS Newswire

ReleaseID: 617537

VANCOUVER, BC / ACCESSWIRE / November 19, 2020 / Tinka Resources Limited ("Tinka" or the "Company") (TSXV:TK)(BVL:TK)(OTC PINK:TKRFF) is pleased to provide an update on the ongoing drill program at the Company's 100% owned Ayawilca zinc-silver project in central Peru.

As at today's date, 2,000 metres have been drilled in the 2020 program and the overall program is about 30% complete. A third rig has been mobilized to site and has commenced drilling. We now expect the drill program to continue until February 2021, at which time we will take a break in the drilling to compile data and update the project resource estimations.

Three holes have been completed since the program commenced in October (drillholes A20-169, 170, and 171), and three holes are in progress (drillholes A20-172, 173 and 174). Samples for the first two drillholes are in the laboratory, and we expect assay results to be received by the end of November.

Drilling is currently targeting extensions of the Zinc Zone Indicated Resources at the West and South areas (Figure 1), the portions of the resource with the greatest thickness and the highest grades. Drillholes at the Colqui Silver Zone are planned later in the program to test for extensions of high-grade silver mineralization along the Colquipucro Fault.

President and CEO of Tinka, Dr. Graham Carman, stated: "We are pleased with progress of drilling to date, and we look forward to the results from the first drillholes. The arrival of a third rig will speed up the program, while allowing us to also complete a limited number of geotechnical holes within the framework of our work program and budget."

"The prices of industrial metals and precious metals have increased significantly in recent times. In the case of zinc, prices are at 18 month highs (~US$1.20/lb) while inventories remain low. Silver prices have also excelled due to global currency devaluation and fiscal stimulus, with silver prices up over 40% in the past year (~US$24/oz). The sharp move higher in silver is the reason we have been re-emphasizing our silver resources, as Ayawilca has substantial silver in the Zinc Zone and also at our nearby Colqui Silver Zone."

"A Preliminary Economic Assessment (PEA) completed in July 2019 on the Ayawilca Zinc Zone resulted in an after-tax NPV8% of US$363 million (using US$1.20/lb Zn and US$18/oz Ag) with initial capex of US$262 million, which is modest for a base metal project of this size. Tinka is continuing to evaluate ways to add value to the project through optimization of the PEA, which could eventuate in an even more compelling project on the back of an updated resource in 2021."

About Ayawilca: The Ayawilca Zinc Zone (sulphide) contains an estimated 1.8 billion pounds zinc and 5.8 million ounces silver in the Indicated category, and 5.6 billion pounds zinc and 25.2 million ounces silver in the Inferred category (see news release dated November 26, 2018). The Colqui Silver Zone (oxide) contains an estimated 14.3 million ounces silver in the Indicated category and 13.2 million ounces silver in the Inferred category, with mineralization starting from surface (see link to Technical Report dated July 2, 2019).

On behalf of the Board,

"Graham Carman"
Dr. Graham Carman, President & CEO

Investor Information:
www.tinkaresources.com
Rob Bruggeman 1.416.884.3556
rbruggeman@tinkaresources.com
Company Contact:
Mariana Bermudez 1.604.699.0202
info@tinkaresources.com

Figure 1. 3D image of Ayawilca highlighting 2020 drill holes in the current drill program (all with assays pending) and Zinc Zone Indicated Resources

About Tinka Resources Limited  

Tinka is an exploration and development company with its flagship property being the 100%-owned Ayawilca zinc-silver project in central Peru. The Ayawilca Zinc Zone has an estimated Indicated resource of 11.7 Mt grading 6.9% zinc, 15 g/t silver & 0.2% lead and an Inferred resource of 45.0 Mt grading 5.6% zinc, 17 g/t silver & 0.2% lead (dated November 26, 2018). The Colqui Silver Zone (oxide) has an estimated Indicated resource of 7.4 Mt grading 60 g/t silver, and an Inferred resource of 8.5 Mt grading 48 g/t silver occurring from surface (dated May 25, 2016). A Preliminary Economic Assessment for the Zinc Zone was released on July 2, 2019 (see release). The Qualified Person, Dr. Graham Carman, Tinka's President and CEO, and a Fellow of the Australasian Institute of Mining and Metallurgy, has reviewed and verified the technical contents of this release.

Forward Looking Statements: Certain information in this news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively "forward-looking statements"). All statements, other than statements of historical fact are forward-looking statements. Forward-looking statements are based on the beliefs and expectations of Tinka as well as assumptions made by and information currently available to Tinka's management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including, without limitations: timing of planned drill programs and results varying from expectations; delay in obtaining results; expectations regarding the Ayawilca Project PEA; the potential impact of epidemics, pandemics or other public health crises, including the current outbreak of the novel coronavirus known as COVID-19 on the Company's business, operations and financial condition; changes in world metal markets; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; equipment failure, unexpected geological conditions; imprecision in resource estimates or metal recoveries; success of future development initiatives; competition and operating performance; environmental and safety risks; delays in obtaining or failure to obtain necessary permits and approvals from local authorities; community agreements and relations; and, other development and operating risks. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein. Although Tinka believes that assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Except as may be required by applicable securities laws, Tinka disclaims any intent or obligation to update any forward-looking statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release

SOURCE: Tinka Resources Limited

ReleaseID: 617538

BEVERLY HILLS, CA / ACCESSWIRE / November 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce Dr. Greg Berk, M.D. has joined the Company's Board of Directors.

Dr. Greg Berk is an Independent Director of the Company. Dr. Berk is a senior oncology drug development consultant. Dr. Berk previously served as Chief Medical Officer at Verastem. Dr. Berk was President, Chief Medical Officer, and Board Member of Sideris Pharmaceuticals. From May 2012 until January 2014, Dr. Berk was Chief Medical Officer of BIND Therapeutics. Previously, Dr. Berk was Chief Medical Officer at Intellikine, a privately held biotechnology company focused on the discovery and development of novel PI3 Kinase and mTOR inhibitors. Intellikine was acquired by Takeda/Millennium in January 2012. Dr. Berk was previously Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the company's overall clinical strategy, including efforts to expand the indications for their lead clinical program (Abraxane®), as well as oversee the clinical development of their entire pipeline. Dr. Berk also served on the integration leadership team during the Celgene (Trading: CLEG) acquisition of Abraxis in 2010. Dr. Berk obtained his medical degree from Case Western Reserve University, and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology, at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group oncology clinical trials, including the pivotal trials for Gleevec® and Avastin®. The Board of Directors believes that Dr. Berk's qualifications to sit on the Board include his experience building companies and bringing oncology drugs to the market, his medical credentials and experience in oncology, and his pharmaceuticals industry experience and knowledge.

Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased to welcome Greg to the Company's Board of Directors, and we look forward to working with Greg as we advance TriKE™ in clinical development for the treatment of cancer and other diseases."

About GTB-3550 Trispecific NK cell Engager (TriKE™)
GTB-3550 is the Company's first TriKE™ product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The natural killer (NK) cell stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. We intend to study GTB-3550 in CD33 positive leukemias such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies.

About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary Tri-specific Killer Engager (TriKE™) platform. Our TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize cancer therapies using proprietary TriKE™ technologies.

Forward-Looking Statements
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Form 10-K for the fiscal year ended December 31, 2019 in the section titled "Risk Factors" in Part I, Item 1A and in our subsequent Form 10Q Quarterly filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

For more information, please visit www.gtbiopharma.com.

SOURCE: GT Biopharma, Inc

ReleaseID: 617458

TORONTO, ON / ACCESSWIRE / November 19, 2020 / Murchison Minerals Ltd. ("Murchison" or the "Company") (TSXV:MUR) is pleased to provide an update on the recent prospecting results on its HPM Ni-Cu-Co project in Quebec. Results of the reconnaissance sampling program completed by Orix Geoscience 2018 Inc. confirm the widespread nature of Ni-Cu-Co mineralization across the HPM project area. Grab sample assay results reach up to 0.16% cobalt, 0.499% copper and 0.526% nickel.

Program Highlights

Strong gossan zones sampled 2 km to the northeast of the Barre de Fer occurrence yielded 0.53% Ni, 0.5% Cu, and 903 ppm Co hosted in gabbro-gabbronorite with 30-40% semi-massive to net-textured pyrrhotite and trace chalcopyrite.
Sampling of the Syrah occurrence 0.5 km to the east of Barre de Fer yielded 0.36% Ni, 0.18% Cu, and 409 ppm Co hosted in norite-gabbronorite with 3-7% pyrrhotite.
Sampled massive pyrite-pyrrhotite hosted in pyroxenite boulders at the base of a cliff 2.5 km to the southeast of Barre de Fer contained 0.3% Ni, 0.27% Cu, and 0.16% Co.

The 2020 HPM reconnaissance program focused on the prospecting of anomalies identified by past airborne electromagnetic (EM) surveys and further investigation of known sulphide occurrences. 43 field samples were collected around 10 areas of interest coincident with airborne EM anomalies across the property and which were then surveyed using a Beep Mat instrument to identify near-surface conductors associated with sulphide mineralization.

Seven gossanous zones with sulphide mineralization were sampled, and Beep Mat conductors were outlined in preparation for future follow-up work. The gossan zones are several metres wide and mostly observed along the side of NNW-SSE striking cliff faces; the thickness and extent of the gossan zones are undetermined due to overburden cover. Gossans are surface expressions of iron bearing rock, often in the form of sulphides, which has been weathered to rusty reddish-brown colour by weathering and leaching of the sulphide mineralization. Gossans are a common key indicator of a sulfide deposit below and often the primary target for prospecting sulfide deposits.

JC Potvin, Murchison President and CEO, noted: "The HPM project has numerous gossanous nickel/copper/cobalt-bearing outcrops spatially linked to airborne EM anomalies, which is quite encouraging. It is well known that Voisey's Bay was originally prospected and mapped as a pyritic gossan, and the fact that the first sampling yielded little or no anomalous metal concentrations at that time no doubt reflects the leaching of metals from the deeply weathered surficial cap."

Continued investigations for economic Ni-Cu-Co sulphide deposits at HPM will include further detailed prospecting of known occurrences and existing targets with follow-up on surface geophysical surveys to establish drill targets. In addition, regional airborne EM surveys will provide additional targets for ground follow-up.

Historically, exploration and drilling on the HPM property focused on the immediate area around Barre de Fer. The anomalous Ni-Cu-Co results from mafic intrusions 0.5-2.5 km outside of that area, obtained from the current reconnaissance program, demonstrate the potential for a mineralization system that is larger than previously thought.

The 58 km2 HPM property lies within the Grenville Province's Allochthonous Belt and is host to numerous Ni-Cu-Co showings associated with mafic to ultramafic intrusions, including the high-grade Barre de Fer magmatic nickel sulphide occurrence. The Barre de Fer occurrence returned up to 1.74% Ni, 0.90% Cu, and 0.09% Co over 43.18m in historic diamond drilling. Results from this short reconnaissance prospecting program in conjunction with historic results provide additional encouragement for a follow-up program at HPM.

Historic drilling has outlined the presence of semi-massive to massive Ni-Cu sulphide mineralization at Barre de Fer over a 300-metre strike extent and to a depth of 280 metres. The high-grade Barre de Fer mineralization and surrounding Ni-Cu sulphide occurrences and gossanous zones could represent the surface indications of greater mineralization at depth. Further interpretation, field work and drilling are required to determine the potential for multiple economic deposits in this the project area.

Magmatic Ni-Cu-Co mineralization is the principal exploration target at the HPM project. Worldwide, the most important magmatic deposits occur almost exclusively at the base of their associated mafic and ultramafic igneous bodies and are related to sulfur saturation, sulfide precipitation and density settling within the magma chamber. Surface sampling of low-grade mineralization at the top of the magmatic intrusion can indicate strong mineralization at depth.

Project Location

Map of 2020 field sample locations displayed by Ni%, with the last three digits of the sample numbers and best assay results

Airborne EM Coverage

Only a part of the claim package has been covered by past airborne EM surveys. A detailed magnetic survey was recently completed, and the data will be released as soon as the analysis has been finalized, expected in a few weeks. Murchison considers the area highly prospective and plans to conduct additional prospecting and to cover the area with electromagnetic geophysical surveys in the future.

2020 Prospecting Targets

2020 field targets based on the 2008 AeroTEM survey and 2001 THEM survey anomalies (triangles)

Location Map of HPM Exploration Target Areas & Names of Mineral Showings

Semi-massive to net-textured pyrrhotite with trace chalcopyrite in gabbro/ gabbronorite (cliff gossan zone), "4048" Area, Middle HPM

Gossan area on side of cliff between Malbec gossan showing and "4048" gossan showing, on an east-west trend. Overall trace to 1% pyrrhotite, locally up to 2-3%; hosted in gabbro / gabbronorite. Located between Malbec and "4048" Area

Two mineralized cliff gossan areas west of Malbec showing straddling a 300 m long EM conductor

QB4048 Area, Middle HPM: Historical sample containing 0.83% Ni, 0.81% Cu. Large gossan/oxidized zone seen on side of cliff visited and sampled, containing semi-massive to net-textured pyrrhotite with trace chalcopyrite in gabbro / gabbronorite

The Barre de Fer area with the 2008 AeroTEM conductors and HLEM conductors. The Beep Mat gave conductive responses coincident with HLEM conductors, as well as to the south of the Syrah occurrence

West of Barre de Fer Area – THEM Conductors: Area of THEM conductors to the west of Barre de Fer was prospected with a beep mat. Few airborne conductors were picked up with the beep mat as the area is heavily swamp covered and could not be sampled

Pervasive strong gossan zone on side of cliff east of Barre de Fer drilling area. Most surface sulphides are weathered out of gossan

Barre de Fer Area – South: Moderate gossan south of Barre de Fer drilling area. Up to 5% interstitial/ blebby pyrrhotite with trace chalcopyrite hosted in gabbro. Lines up with 2008 HLEM (Max Min) conductor (MM-13) (sample #X024589)

Syrah Showing Area: Beep mat used to locate conductors in a 20-30m wide area to the south east of the Syrah showing. Overburden too thick (0.7m of soil/moss) to sample the located beep mat conductors

PYC Showing Area: Several gossanous zones with 1-5% disseminated sulphides were located and sampled in the PYC area including an approximately 100m long (to the NW) and 30m wide outcrop zone of gossan with 1-5% disseminated sulphides. The PYC EM conductor, traced for 1,400 m, was historically explored by a single hole drill hole which intersected 15.3 m @0.28% Ni, 0.14% Cu 0.06% Co (0.84% Cu equivalent)

East HPM Target Area

Most EM airborne conductors targeted are under lakes/swamp, hence could not be readily mapped nor sampled; one conductor picked up with beep mat in swampy area. A beep mat GPS tracklog was kept for this area.

SAMPLE ASSAYS

The sampling demonstrated the widespread distribution of nickel/copper/cobalt mineralization across the property.

QA/QC

All rock samples were submitted for preparation to ALS Val D'Or, Canada and processed at ALS Vancouver, Canada. They were analyzed using a four-acid digest and ICP-AES method (ME-ICP61). ALS Canada is an ISO certified and accredited laboratory.

QP

The foregoing scientific and technical disclosures have been reviewed by Paul Nagerl, P. Geo., a qualified person as defined by National Instrument 43-101. Mr. Nagerl is an independent consultant to Murchison and the HPM project.

About the HPM Project

The HPM property holdings cover the prospective geological unit that hosts significant nickel/copper/cobalt mineralization identified by a total of 32 diamond drill holes (6,479 m) completed in 2001-2 and 2008. Murchison holds a 100% interest over 58.3 km2 of contiguous mineral claims.

Murchison also owns the Brabant‐McKenzie VMS Project in Saskatchewan.

The Brabant-McKenzie project is located 175 kilometres northeast of La Ronge, Saskatchewan and

approximately three kilometres from the community of Brabant Lake. The area is accessed year-round

via provincial Highway 102 and is serviced by grid power.

Brabant‐McKenzie VMS Deposit

The project consists of one mining lease, which hosts the Brabant-McKenzie VMS deposit, and additional mineral claims totalling 627 square kilometres, which cover approximately 57 kilometres of strike length over favourable geological horizons, multiple known mineralized showings and identified geophysical conductors.

About Murchison Minerals Ltd. (TSXV: MUR)

Murchison is a Canadian‐based exploration company focused on the exploration and development of the 100%-owned Brabant‐McKenzie zinc‐copper‐silver project in north‐central Saskatchewan. The Company also has a 100% interest in the HPM nickel‐copper‐cobalt project in Quebec. Murchison has 78.7 million shares issued and outstanding.

Additional information about Murchison and its exploration projects can be found on the Company's website at www.murchisonminerals.com. For further information, please contact:

Jean‐Charles (JC) Potvin, President and CEO
jcpotvin@murchisonminerals.com

Erik H Martin, CFO
Tel: (416) 350‐3776
info@murchisonminerals.com

Cathy Hume, CHF Capital Markets, CEO
Tel: 416-868-1079 x 231
cathy@chfir.com

Forward‐Looking Information

Certain information set forth in this news release may contain forward‐looking information that involves substantial known and unknown risks and uncertainties. This forward‐looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward‐looking information. The parties undertake no obligation to update forward‐looking information except as otherwise may be required by applicable securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Murchison Minerals Ltd.

ReleaseID: 617501

NEW YORK, NY / ACCESSWIRE / November 19, 2020 / After a year of challenges and uncertainty, CEO Paul Vigario is giving the team at SurfCT the long weekend of Thanksgiving off.

Thanksgiving is considered one of the quintessential American holidays, and due to the COVID-19 pandemic, many people have had to spend holidays apart in 2020. Vigario understands the intrinsic value of a healthy work-life balance. He himself loves spending time with his three-year-old daughter and family.

Founded by CEO Paul Vigario while obtaining a Computer Information degree at the University of Connecticut in 2003, SurfCT has grown to be the number one dental information technology company in the United States. They are an award-winning and internationally recognized company that caters to dentists and elective healthcare practices.

SurfCT understands dental technology, elective healthcare, integrated care, digital workflow and practice automation like no other in the healthcare industry. They have over two decades of experience in dental technology, dental office design, dental systems, med spa and healthcare innovation for private practices.

"Our ability to automate a practice makes us the technology company of choice for doctors in private practice such as dentists, cosmetic dentists, endodontists, oral surgeons, orthodontists, and others like optometrists, plastic surgeons, med spas and even veterinarians. Our growth is a direct result of successful doctor referrals who have experienced the results of practice automation and practice growth by leveraging SurfCT knowledge and experience" Paul Vigario explains.

Being client-centric and building systems to help those clients grow is what makes them different. But besides being client-centric, SurfCT also cares deeply about its Team Members.

"There is no comparison with who we are as a team and what we do for our clients. We build specific systems for doctors, for the way they want to practice, connecting their vision and treatment philosophies to elevate their brand and practice ultimately getting to the ‘why' connecting it all to how they want to live their life. We change our doctors lives with practice automation. There really is no competition for SurfCT." Paul Vigario says. "Most private practices before they meet us run like a local coffee shop. With our systems, we turn them into Starbucks. Does Starbucks compete with the local coffee shop owner?"

With the extra time off, Vigario expects Team Members to come back with new energy to successfully close out 2020 at SurfCT, which continues to set the technology bar and tone in the dental and elective healthcare industry.

CONTACT:
Paula Henderson
202-539-7664
phendersonnews@gmail.com

About VIP Media Group:
VIP Media Group is a hybrid PR agency. Their diverse client base includes top-class entrepreneurs, public figures, influencers, and celebrities.

SOURCE: VIP Media Group

ReleaseID: 617695